(Q38061199)

28 August 2017

1 reference

title

Lung cancer chemoprevention: difficulties, promise and potential agents? (English)

1 reference

28 August 2017

Konstantine Dragnev

1

1 reference

28 August 2017

Ming You

series ordinal

2

1 reference

28 August 2017

Yian Wang

series ordinal

3

1 reference

28 August 2017

Ronald Lubet

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

21 November 2012

1 reference

Expert Opinion on Investigational Drugs

28 August 2017

published in

1 reference

28 August 2017

volume

22

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

35-47

1 reference

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Exemestane for breast-cancer prevention in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Celecoxib for the prevention of sporadic colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Chemoprevention of lung cancer: concepts and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Chemoprevention--history and general principles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Chemoprevention of lung cancer by tea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Molecular basis for chemoprevention by sulforaphane: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Animal models of lung cancer characterization and use for chemoprevention research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Nuclear retinoid receptors and the transcription of retinoid-target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Bexarotene: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Prevention of mouse lung tumors by targretin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Prevention of lung cancer progression by bexarotene in mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Modulation by bexarotene of mRNA expression of genes in mouse lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Aerosolized bexarotene inhibits lung tumorigenesis without increasing plasma triglyceride and cholesterol levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Nonclassical retinoids and lung carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Gefitinib for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

EGFR testing in lung cancer is ready for prime time

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

The BATTLE trial: personalizing therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Bexarotene and erlotinib for aerodigestive tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

NRF2 and cancer: the good, the bad and the importance of context.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Regulatory mechanisms controlling gene expression mediated by the antioxidant response element

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Inflammation meets cancer, with NF-κB as the matchmaker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Lung cancer chemoprevention with celecoxib in former smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Biological activity of celecoxib in the bronchial epithelium of current and former smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Aerosolized 3-bromopyruvate inhibits lung tumorigenesis without causing liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Oral iloprost improves endobronchial dysplasia in former smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Airway PI3K pathway activation is an early and reversible event in lung cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Detection and localization of intraepithelial neoplasia and invasive carcinoma using fluorescence-reflectance bronchoscopy: an international, multicenter clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

Genetic variation and antioxidant response gene expression in the bronchial airway epithelium of smokers at risk for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

The BATTLE to personalize lung cancer prevention through reverse migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.731392

10.1517/13543784.2013.731392

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference